BusinessWire

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global
Cryostat Market Analysis & Trends - Industry Forecast to 2025"
report to their offering.


MONTEVIDEO, Uruguay--(BUSINESS WIRE)--Arcos Dorados Holdings Inc. (NYSE:ARCO) (“Arcos Dorados” or the
“Company”) today announced that it intends to offer senior unsecured
notes (the “Notes”) in a private placement to qualified institutional
buyers in accordance with Rule 144A under the Securities Act of 1933, as
amended (the “Securities Act”), and outside the United States to non
U.S. persons in accordance with Regulation S under the Securities Act.

NEW YORK--(BUSINESS WIRE)--#CSR--Following are the latest Corporate Social Responsibility news releases
and story ideas available from Business Wire. These recaps, curated by
Business Wire, provide reporters and bloggers around the globe instant
access to the latest news releases, providing relevant and trending
content to share with their audiences. Discover more news via Business
Wire’s Hot Topic recaps or create a custom news feed specific to your

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global
Cardiac Monitoring Market Analysis & Trends - Industry Forecast to 2025"
report to their offering.


Revenues: € 7.1 million, +18x year-on-year Backlog of orders: € 6.5 million as of today, thanks to € 12.1
million order intake of the last 12 months Gross margin: € 3.2 million, equal to 46% of revenues Internationalization: approx. 53% of revenues from
installations outside Europe
ReActiv8-B Clinical Trial - on track to complete enrolment around
the end of 2017, with data availability in 2018 First sale and implant of ReActiv8 in Germany announced in February
2017 CE Marking based on positive results from ReActiv8-A Clinical
Trial, one year data showed performance maintained
ReActiv8-B Clinical Trial - on track to complete enrolment around
the end of 2017, with data availability in 2018 First sale and implant of ReActiv8 in Germany announced in February
2017 CE Marking based on positive results from ReActiv8-A Clinical
Trial, one year data showed performance maintained

WHEATON, Ill.--(BUSINESS WIRE)--First Trust Advisors L.P. (“FTA”) announces the declaration of
distributions for 91 exchange-traded funds advised by FTA.


The following dates apply to today’s distribution declarations:

LANCASTER, Pa.--(BUSINESS WIRE)--Fulton Financial Corporation (NASDAQ: FULT) today announced that it has
made an investment in a new class of noncumulative, nonvoting perpetual
preferred stock authorized and issued by United Bancshares, Inc.
(United), following receipt of approval to make the investment from the
Pennsylvania Department of Banking and Securities.

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma’s innovative and patented preservative-free multidose
Ophthalmic Squeeze Dispenser is available for patients in the U.S.
prescription market for the first time with Allergan’s RESTASIS
MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%.

Pages